What are the Historical Developments and Current Growth Metrics of the Viral Vectors And Plasmid DNA Market?
The viral vectors and plasmid dna market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for viral vectors and plasmid dna has been expanding rapidly. It is projected to rise from $1.05 billion in 2024 to $1.2 billion in 2025, marking a compound annual growth rate (CAGR) of 14.8%.
Factors contributing to growth during the historical period include a rise in cancer cases, heightened awareness about gene therapy, a growing patient population, improved access to healthcare services, and an increased demand for personalized medicine.
What Is The Projected Growth Of The Viral Vectors And Plasmid DNA Template Market?
The viral vectors and plasmid dna market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for viral vectors and plasmid DNA is predicted to witness substantial growth over the next several years. The market is anticipated to reach $1.66 billion by 2029, reflecting a compound annual growth rate (CAGR) of 8.4%.
The projected growth within this forecast period can be linked to the emergence of therapeutic applications, response to the COVID-19 pandemic, increased investment, and worldwide expansion. The future trend prognosis shows advancements in the manufacturing technology of viral vector and plasmid DNA, improvements in gene editing, personalized vectors, scalability and efficient production, safe and high-quality standards, non-viral delivery methods, and global collaboration.
What Are The Key Drivers Fueling Growth In The Viral Vectors And Plasmid DNA Market?
The surge in worldwide cancer occurrences is fuelling the market for viral vector and plasmid DNA. Key contributors to most cancers encompass obesity, smoking, alcohol intake and unhealthy dietary habits. For example, the American Cancer Society anticipated in January 2022, that there will be around 1.9 million fresh cancer cases and 609,360 cancer-related deaths in the US, which approximately translates to 1,670 death incidents daily. The four most prevalent cancer types around the globe are lung, prostate, bowel, and breast cancer in women, making up 43 percent of all the newly diagnosed cases. The projected increase in worldwide cancer occurrences is foreseen to escalate the demand for the viral vectors and plasmid DNA market in the forthcoming years.
What Are The Principal Market Segments In The Global Viral Vectors And Plasmid DNA Industry?
The viral vectors and plasmid dna market covered in this report is segmented –
1) By Product: Plasmid DNA, Viral Vectors
2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases
3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications
4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies
Subsegments:
1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA
2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors
Pre-Book The Viral Vectors And Plasmid DNA Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Viral Vectors And Plasmid DNA Market?
The prohibitive pricing of gene therapies poses a significant obstacle in the viral vectors and plasmid DNA market. Gene therapy costs can fluctuate between $0.2 million to $2.1 million. For example, Gilead's product, Yescarta, a form of gene therapy, is priced at roughly $0.3 million, while Bluebird Bio's Letiglobin, another gene therapy, is priced at approximately $2.1 million. The high cost can be attributed to factors such as government regulations, manufacturing expenses, among others. Consequently, the exorbitant cost of gene therapies is impeding the growth of the viral vector & plasmid DNA market.
Who Are the Key Players In The Viral Vectors And Plasmid DNA Market?
Major companies operating in the viral vectors and plasmid dna market include:
• FUJIFILM Diosynth Biotechnologies
• FinVector Vision Therapies
• Lonza Group AG
• Cobra Biologics and Pharmaceutical Services
• Brammer Bio
• ??n?k? ??r??r?t??n
• Cell and Gene Therapy Catapult
• VGXI Inc.
• MassBiologics
• Sanofi
• Spark Therapeutics
• UniQure NV
• Thermo Fisher Scientific
• VIROVEK
• SIRION Biotech GmbH
• ALDEVRON
• Oxford BioMedica
• PlasmidFactory GmbH & Co. KG
• Biovian Oy
• BioReliance Corporation
• 4D Molecular Therapeutics
• Renova Therapeutics
• Shenzhen SiBiono GeneTech Co.
• Vigene Biosciences Inc.
• Novasep
• Genzyme Corporation
• Oxford Gene Technology
• Richter-Helm
• ??l?n NV
• MolMed
• Merck KGaA Inc.
• Catalent Inc.
• WuXi AppTec
• GenScript Biotech Corporation
• Eurogentec
• Creative Biogene
What Are The Regional Insights Into The Viral Vectors And Plasmid DNA Market?
North America was the largest region in the viral vectors and plasmid DNA market in 2024. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
